2,497 publications from this institution
We thank Foster and colleagues for their comments.1 2 Projections of disease progression that are based on natural history studies from tertiary referral centres may exaggerate hepatitis C virus (HCV) related morbidity and mortality. Inception cohort and epidemiological data suggest that only a minority of infected people will progress to end stage liver disease over their lifetime.1 Foster and colleagues repeatedly asserted that treatment is effective, but the cited evidence cannot show this.3 4 5 Van der Meer summarised …
Sulfamethoxazole-trimethoprim is the superior regimen, and low doses could improve tolerance without losing effectiveness for primary prophylaxis. Low doses of dapsone reduce toxic effects, but at the expense of some loss of efficacy. There are few data on the use of low-dose regimens for secondary prophylaxis. High doses of aerosolized pentamidine may improve the efficacy of this regimen. Aerosolized pentamidine is inadequate for prevention of toxoplasmosis, and strategies that improve the tolerance of oral regimens may increase effectiveness in preventing toxoplasmosis.
The proposed algorithms can be routinely applied in meta-analyses as standardized sensitivity analyses for heterogeneity. Caution is needed evaluating post hoc which specific studies are responsible for the heterogeneity.
Systemic sclerosis is a rare and potentially devastating connective tissue disease. It is highly heterogeneous in terms of clinical presentation, extent and severity of organ involvement, immunologic abnormalities, and clinical course. Although clinical outcomes appear to have improved in recent years, the disease continues to cause substantial excess mortality. In this review, we have systematically collected the published studies addressing the mortality burden in patients with scleroderma in comparison with the general population, as well as studies exploring the most important potential predictors of mortality. Results of these studies are presented and discussed, with emphasis on methodological limitations. Suggestions are made for the design, conduct, and reporting of further research on these themes.
IPsec is the standard suite of protocols for network-layer confidentiality and authentication of Internet traffic. The IPsec protocols, however, do not address the policies for how protected traffic should be handled at security end points. This article introduces an efficient policy management scheme for IPsec, based on the principles of trust management. A compliance check is added to the IPsec architecture that tests packet filters proposed when new security associations are created for conformance with the local security policy, based on credentials presented by the peer host. Security policies and credentials can be quite sophisticated (and specified in the trust-management language), while still allowing very efficient packet-filtering for the actual IPsec traffic. We present a practical portable implementation of this design, based on the KeyNote trust-management language, that works with a variety of UNIX-based IPsec implementations. Finally, we discuss some applications of the enhanced IPsec architecture.
A high speed CMOS signalling interface for application in multiprocessor interconnection networks has been developed. The interface utilizes 1-V push-pull drivers, a Delay Line PLL and sampling of the data on both half-periods of the clock. In order to increase the noise immunity of the reception, current-integrating receivers are used to sample the data in the input pads. Chips fabricated in 0.8-/spl mu/m CMOS technology achieve transfer rates of 740 Mbits/sec/pin operating from a 3.3-V supply with a bit error rate of less than 10/sup -14/.
Our results exclude the presence of large and frequent differences in the effect size estimates between men and women for the established loci in the seven common diseases explored. Documenting small differences in genetic effects between men and women requires large studies and systematic evaluation.
Extract HTML view is not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button. Extended abstract of a paper presented at Microscopy and Microanalysis 2005 in Honolulu, Hawaii, USA, July 31--August 4, 2005
Abstract Background Post‐pandemic years are characterized by widespread previous population immunization against COVID‐19. Whether and for whom COVID‐19 vaccinations are still justified is unclear. We use nationwide estimates of IFR and literature‐derived estimates of vaccine effectiveness (VE) to calculate numbers needed to vaccinate to prevent one COVID‐19 death (NNV) and for one life‐year saved (LYS) in Austria in 2024. Methods In this retrospective analysis, we calculate SARS‐CoV‐2 IFR during 2024 in Austria according to previously published wastewater‐based infection estimates and available mortality data. Using literature‐derived VE estimates, we calculate NNV to prevent one COVID‐19 death and for one LYS in strata according to age groups, nursing home residency and vaccination in 2024. We repeat analyses with sensitivity range values of parameters. Results In 2024, total IFR was .048%. NNV (LYS) in the age groups 0–19, 20–39, 40–59, 60–74 and 75–84 years was very high: i.e. 5,497,526 (151,570), 2,432,498 (92,614), 415,714 (24,777), 35,925 (3748) and 4882 (1009), respectively, in community dwellers. In the 85+ years age group, IFRs of unvaccinated/vaccinated were .91%/.77% for community dwellers and 1.22%/1.04% for nursing home residents. The 85+ year age group had NNV estimates of 1215 and 907 (LYS: 525 and 1896) in community dwellers and nursing home residents, respectively. Sensitivity analyses yielded LYS < 1000 only under some favourable assumptions in the 75–84 and 85+ years old age strata. Conclusions In 2024 in Austria, SARS‐CoV‐2 IFR was low and NNV and LYS of COVID‐19 vaccinations correspondingly non‐favorably high, even for very old individuals.